Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin)

Clinical Infectious Diseases

Volumn 30, Issue 2, 2000, Pages 403-404

  McNeil, Shelly A ^a   Clark, Nina M ^a   Chandrasekar, P H ^b   Kauffman, Carol A ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; LINEZOLID; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOOD CULTURE; CASE REPORT; CLOSTRIDIUM DIFFICILE; COLITIS; ENTEROCOCCUS FAECIUM; GASTROINTESTINAL HEMORRHAGE; HOSPITAL INFECTION; HUMAN; MALE; PRIORITY JOURNAL; VEIN THROMBOSIS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; BONE MARROW TRANSPLANTATION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENTEROCOCCUS FAECIUM; FOLLOW-UP STUDIES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OXAZOLES; OXAZOLIDINONES; POSTOPERATIVE COMPLICATIONS; TREATMENT FAILURE; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN;

EID: 0034053853     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313669     Document Type: Article

References (9)

1. 1. Noskin GA. Vancomycin resistant enterococci: clinical, microbiological and epidemiological features. J Lab Clin Med 1997; 130:14-20.
2. 2. Finch RG. Antibacterial activity of quinupristin/dalfopristin: rationale for clinical use. Drugs 1996; 51(Suppl 1):31-7.
3. 3. Bonilla HF, Perri MG, Kauffman CA, Zervos MJ. Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium. Diagn Microbiol Infect Dis 1996; 25:127-31.
4. 4. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC. In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996; 40:1745-7.
5. 5. Bostic GD, Perri MB, Thal LA, Zervos MJ. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci. Diagn Microbiol Infect Dis 1998; 30:109-12.
6. 6. Furlong WB, Rakowski TA. Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with vanA/vanB resistance patterns. Clin Infect Dis 1997; 25:163-4.
7. 7. Aeschlimann JR, Zervos MJ, Rybak MJ. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. Antimicrob Agents Chemother 1998; 42: 2710-7.
8. 8. Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998; 42:721-4.
9. 9. Noskin GA, Siddiqui F, Stosor V, Kruzynski J, Peterson LR. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis 1999; 28:689-90.